Enliven Therapeutics, Inc.
ELVNNasdaq
$53.20
↑ +4.6%Jul 17 close · end-of-day
Price
1Y↑ +147.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.3B
Enterprise Value
$2.9B
P/E
—
P/S
—
P/B
7.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$98.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-21.8%
ROIC
-9488.8%
Debt / Equity
—
Net Cash
$452.4M
Return 1Y
+127.9%
Company profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
- CEO
- Samuel S. Kintz
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Colorado
- Website
- www.enliventherapeutics.com
Management & directors
- Collins Helen LouiseCHIEF MEDICAL OFFICER
- Hohl BenjaminCHIEF FINANCIAL OFFICER
- Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER
- Patel AnishCHIEF OPERATING OFFICER
- Kintz SamuelPRESIDENT AND CEO
Roles derived from SEC Form 4 filings.
Earnings
ELVN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.38↓ -33.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$41.7M | -$24.8M | -$38.8M | -$83.5M | -$104.6M | -$119.7M |
| Net income | -$41.4M | -$24.7M | -$37.7M | -$71.6M | -$89.0M | -$103.7M |
| Diluted EPS | — | -$10.73 | -$12.05 | -$2.01 | -$1.89 | -$1.83 |
| Operating cash flow | -$37.4M | -$19.1M | -$32.1M | -$61.3M | -$73.2M | -$70.3M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$24.6M | -$27.1M | -$26.9M | -$31.7M | -$28.6M | -$25.1M | -$34.3M | -$27.8M |
| Net income | -$19.9M | -$23.2M | -$23.2M | -$28.5M | -$25.3M | -$20.1M | -$29.7M | -$23.6M |
| Diluted EPS | -$0.41 | -$0.48 | -$0.46 | -$0.57 | -$0.49 | -$0.32 | -$0.45 | -$0.38 |
| Operating cash flow | -$20.4M | -$12.2M | -$17.2M | -$24.1M | -$17.1M | -$13.3M | -$15.8M | -$19.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Kunkel Lori Anne | Sale | 5,889 | $50.84 | $299,421.49 | filing |
| 2026-07-06 | Kunkel Lori Anne | Sale | 4,111 | $49.98 | $205,481.76 | filing |
| 2026-06-22 | ORBIMED ADVISORS LLC | Sale | 787,024 | $45.38 | $35.7M | filing |
| 2026-06-22 | ORBIMED ADVISORS LLC | Sale | 46,776 | $45.00 | $2.1M | filing |
| 2026-06-22 | ORBIMED ADVISORS LLC | Sale | 24,846 | $45.38 | $1.1M | filing |
| 2026-06-22 | ORBIMED ADVISORS LLC | Sale | 1,477 | $45.00 | $66,465.00 | filing |
| 2026-06-17 | Hohl Benjamin· CHIEF FINANCIAL OFFICER | Sale | 3,401 | $43.86 | $149,179.42 | filing |
| 2026-06-17 | Collins Helen Louise· CHIEF MEDICAL OFFICER | Sale | 2,599 | $43.87 | $114,018.39 | filing |
| 2026-06-17 | Hohl Benjamin· CHIEF FINANCIAL OFFICER | Sale | 1,379 | $42.79 | $59,000.52 | filing |
| 2026-06-17 | Hohl Benjamin· CHIEF FINANCIAL OFFICER | Sale | 1,238 | $44.75 | $55,397.41 | filing |
| 2026-06-17 | Collins Helen Louise· CHIEF MEDICAL OFFICER | Sale | 1,268 | $42.83 | $54,304.64 | filing |
| 2026-06-17 | Collins Helen Louise· CHIEF MEDICAL OFFICER | Sale | 1,133 | $44.74 | $50,693.82 | filing |
| 2026-06-17 | Hohl Benjamin· CHIEF FINANCIAL OFFICER | Option exercise | 6,018 | $2.48 | $14,924.64 | filing |
| 2026-06-17 | Collins Helen Louise· CHIEF MEDICAL OFFICER | Option exercise | 5,000 | $2.48 | $12,400.00 | filing |
| 2026-06-15 | ORBIMED ADVISORS LLC | Sale | 272,322 | $45.02 | $12.3M | filing |
| 2026-06-15 | ORBIMED ADVISORS LLC | Sale | 9,086 | $45.02 | $409,051.72 | filing |
| 2026-06-05 | Kunkel Lori Anne | Sale | 7,779 | $34.28 | $266,659.45 | filing |
| 2026-06-05 | Kunkel Lori Anne | Sale | 1,867 | $35.36 | $66,012.08 | filing |
| 2026-06-05 | Kunkel Lori Anne | Sale | 354 | $35.82 | $12,679.82 | filing |
| 2026-05-18 | Collins Helen Louise· CHIEF MEDICAL OFFICER | Sale | 3,475 | $39.53 | $137,380.65 | filing |
| 2026-05-18 | Collins Helen Louise· CHIEF MEDICAL OFFICER | Sale | 1,302 | $40.25 | $52,401.98 | filing |
| 2026-05-18 | Collins Helen Louise· CHIEF MEDICAL OFFICER | Option exercise | 5,000 | $2.48 | $12,400.00 | filing |
| 2026-05-18 | Collins Helen Louise· CHIEF MEDICAL OFFICER | Sale | 223 | $41.21 | $9,188.76 | filing |
| 2026-04-17 | Collins Helen Louise· CHIEF MEDICAL OFFICER | Sale | 2,441 | $48.06 | $117,303.48 | filing |
| 2026-04-17 | Collins Helen Louise· CHIEF MEDICAL OFFICER | Sale | 2,419 | $47.39 | $114,635.44 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.